Connect your AI

Crinetics Pharmaceuticals CRNX Earnings yield

Earnings yield at other companies

Neurocrine BiosciencesNBIX

5.1%+2.3pp

Corcept TherapeuticsCORT

1.1%0.0pp

Viking TherapeuticsVKTX

-12.6%-31.7pp

Catalyst PharmaceuticalCPRX

7.3%+0.6pp

Ultragenyx PharmaceuticalRARE

-29.6%+144pp

Mineralys Therapeutics, Inc.MLYS

-6.8%-2.7pp

Other financials

Income statement

Revenue$10.7M+2,873%

Gross profit$10.5M+2,818%

Operating income-$140.4M-26.0%

Net income-$127.8M-32.1%

EPS (diluted)-$1.23-18.3%

Balance sheet

Cash & equivalents$115.1M+20.1%

Total debt$47.9M-5.8%

Total equity$1.3B+2.1%

Total assets$1.4B+2.9%

Cash flow

Operating cash flow-$124.7M-41.0%

CapEx$820.0K-33.8%

Free cash flow-$125.5M-40.0%

Valuation

Market cap$3.79B+21.9%

Profitability

Gross margin150%-15.6pp

Operating margin-3,020.3%-1,463pp

Net margin-2,747.2%-1,328pp

FCF margin-2,321.7%-1,122pp

Returns & leverage

Return on equity-39.2%+14.5pp

Debt / equity0×0.0×

Current ratio18.6×-3.9×

Where this comes from

Calculated from Crinetics Pharmaceuticals’s reported figures.

net income/market cap=-13.1%

Based on trailing twelve months.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Crinetics Pharmaceuticals's earnings yield?: Crinetics Pharmaceuticals (CRNX) reported earnings yield of -13.1% in Q1 2026.
How has Crinetics Pharmaceuticals's earnings yield changed year-over-year?: Crinetics Pharmaceuticals's earnings yield decreased by 24.1% year-over-year, from -10.5% to -13.1%.
What is the long-term trend for Crinetics Pharmaceuticals's earnings yield?: Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's earnings yield has grown at a -0.9% compound annual growth rate (CAGR), from -11% to -10.5%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.